Date: 2017-10-17
Type of
information: Presentation of results at a congress
phase: preclinical
Announcement: presentation of results at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Application
Company: Vaximm (Germany)
Product: VXM10
Action
mechanism:
Disease:
Therapeutic
area: Cancer - Oncology
Country:
Trial
details:
Latest
news:
- • On October 17, 2017, Vaximm, a biotech company focused on developing oral T-cell immunotherapies, announced that preclinical data with its oral T-cell immunotherapy platform, including one preclinical development candidate, VXM10, are being presented at the upcoming "AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications" being held October 26-30, 2017 in Philadelphia. The poster, "Live attenuated oral Salmonella platform for effective targeting of multiple tumor-associated epitopes and PD-L1," summarizes the immunogenicity and anti-leukemia activity of VXM10, transformed with a eukaryotic expression plasmid encoding the murine programmed death-ligand 1 (PD-L1) protein in an animal model. Multiple oral administrations of VXM10m were generally well tolerated, and no toxicity nor body weight loss were observed. Oral administration of VXM10 produced a strong anti-tumor effect in the FBL-3 leukemia model, with a 100% survival rate 80 days after leukemia challenge in those groups given the highest doses. All long-term surviving mice resisted a re-challenge with FBL-3 cells, demonstrating that vaccination with VXM10m generated a potent memory T-cell response against the leukemia cells. Importantly, full leukemia control was achieved in both prophylactic and therapeutic settings.
Additionally, various polyepitope vaccines encoding dominant epitopes from VEGFR2, Mesothelin, WT1, CEA, and Ovalbumin, induced a significant systemic immunogenicity for up to 6 of 9 epitopes, 10 days after vaccination of healthy mice via the oral route. This study provides further evidence that VAXIMM's oral T-cell vaccination platform can not only be employed to stimulate anti-tumor immunity against the antigen of the immune checkpoint regulatory protein PD-L1, but also against T-cell epitopes encoded by polyepitope constructs. These data pave the way for advancing the development of VXM10 and neoantigen-based vaccines into clinical development.
Is
general: Yes
